FDA rejects Lilly’s BLA for UC drug over manufacturing concerns
Pharmaceutical Technology
APRIL 14, 2023
No concerns related to the clinical data package, safety or the medicine label. Mirikizumab also obtained a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use. The regulator has issued a complete response letter.
Let's personalize your content